Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth

Prostate cancer (PC) is driven by androgen receptor (AR) activity, a master regulator of prostate development and homeostasis. Frontline therapies for metastatic PC deprive the AR of the activating ligands testosterone (T) and dihydrotestosterone (DHT) by limiting their biosynthesis or blocking AR b...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Invest
Päätekijät: Nyquist, Michael D., Ang, Lisa S., Corella, Alexandra, Coleman, Ilsa M., Meers, Michael P., Christiani, Anthony J., Pierce, Cordell, Janssens, Derek H., Meade, Hannah E., Bose, Arnab, Brady, Lauren, Howard, Timothy, De Sarkar, Navonil, Frank, Sander B., Dumpit, Ruth F., Dalton, James T., Corey, Eva, Plymate, Stephen R., Haffner, Michael C., Mostaghel, Elahe A., Nelson, Peter S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Clinical Investigation 2021
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8121509/
https://ncbi.nlm.nih.gov/pubmed/33998604
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI146777
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia